Spotlight on Surgery

Credits: 0.75 AANA / CME / MOCA
Reversing Neuromuscular Blockade: Assessing Current and Emerging Therapies for Improved Outcomes
Matt L. Kirkland, MD, FACS
Vindico Medical Education

Reversing Neuromuscular Blockade: Assessing Current and Emerging Therapies for Improved Outcomes

Start

Activity Details

Free CME with MOCA/AANA
0.75 AMA PRA Category 1 Credit(s)™ with ABA MOCA 2.0; AANA Class A CE Credits
Released: August 31, 2021
Expires: August 30, 2022
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is anesthesiologists, surgeons, nurse anesthetists, and other health care professionals involved in the management of patients undergoing anesthesia.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate the benefits and limitations of current reversal agents including best practices for their use and the value of appropriate monitoring.
  • Apply the latest clinical evidence of current and emerging therapies for the reversal of neuromuscular blocking agents.
  • Utilize a multidisciplinary approach to manage surgical patients in need of deep neuromuscular blockade.
  • Utilize best practices for monitoring patients undergoing neuromuscular blockade.

Activity Description

The introduction of neuromuscular blockade agents (NMBAs) revolutionized the field of anesthesia. However, termination of the effects of these agents remains elusive, and they still have the potential for causing significant adverse outcomes. The cholinesterase inhibitor drugs first used to reverse curare have traditionally been used for reversing all NMBAs, but due to the limitations of these agents and the complications of residual neuromuscular block, development of improved reversal agents has been a priority. A new class of drugs—selective relaxant binding agents—may overcome the limitations of cholinesterase inhibitors, quickly reversing both shallow and deep levels of aminosteroid neuromuscular block. In this educational activity, utilizing an interactive infographic format, expert faculty review the benefits as well as the limitations of current and emerging reversal agents; best practices for monitoring patients undergoing neuromuscular blockade; and the importance of a multidisciplinary approach when managing patients in the surgical setting.

Agenda

Conventional Reversal Agents: Pros and Cons, Best Practices for Monitoring – Cheryl L. Nimmo, DNP, MSHSA, CRNA

Neuromuscular Blockade (NMB) Therapies: Where We Are and Where We Are Going – Anthony L. Kovac, MD

Neuromuscular Blocking Agents (NMBAs): Multidisciplinary Approach to Care – Matt L. Kirkland, MD, FACS

Faculty

Matt L. Kirkland, MD, FACS
Clinical Associate Professor of Surgery
Director Bariatric Surgery Program
Pennsylvania Hospital
Philadelphia, PA

Disclosure: No relevant financial relationships to disclose.


Anthony L. Kovac, MD
Kasumi Arakawa Professor of Anesthesiology
University of Kansas Medical Center
Kansas City, KS

Disclosure:
Contracted Research: Merck


Cheryl L. Nimmo, DNP, MSHSA, CRNA
Associate Clinical Professor
Program Director Nurse Anesthesia
University of New England
Portland, ME

Disclosure: No relevant financial relationships to disclose.

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology™ (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

This program has been prior approved by the American Association of Nurse Anesthesiology for 0.75 Class A CE credits; Code Number 1041138; Expiration Date 8/30/2022.

AANA designates this program as meeting the criteria for up to 0.50 CE Credits in pharmacology/therapeutics.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Only 1 attempt to pass the posttest will be permitted. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or AANA Class A CE Credit Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME with MOCA/AANA
0.75 AMA PRA Category 1 Credit(s)™ with ABA MOCA 2.0; AANA Class A CE Credits
Released: August 31, 2021
Expires: August 30, 2022
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is anesthesiologists, surgeons, nurse anesthetists, and other health care professionals involved in the management of patients undergoing anesthesia.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate the benefits and limitations of current reversal agents including best practices for their use and the value of appropriate monitoring.
  • Apply the latest clinical evidence of current and emerging therapies for the reversal of neuromuscular blocking agents.
  • Utilize a multidisciplinary approach to manage surgical patients in need of deep neuromuscular blockade.
  • Utilize best practices for monitoring patients undergoing neuromuscular blockade.

Activity Description

The introduction of neuromuscular blockade agents (NMBAs) revolutionized the field of anesthesia. However, termination of the effects of these agents remains elusive, and they still have the potential for causing significant adverse outcomes. The cholinesterase inhibitor drugs first used to reverse curare have traditionally been used for reversing all NMBAs, but due to the limitations of these agents and the complications of residual neuromuscular block, development of improved reversal agents has been a priority. A new class of drugs—selective relaxant binding agents—may overcome the limitations of cholinesterase inhibitors, quickly reversing both shallow and deep levels of aminosteroid neuromuscular block. In this educational activity, utilizing an interactive infographic format, expert faculty review the benefits as well as the limitations of current and emerging reversal agents; best practices for monitoring patients undergoing neuromuscular blockade; and the importance of a multidisciplinary approach when managing patients in the surgical setting.

Agenda

Conventional Reversal Agents: Pros and Cons, Best Practices for Monitoring – Cheryl L. Nimmo, DNP, MSHSA, CRNA

Neuromuscular Blockade (NMB) Therapies: Where We Are and Where We Are Going – Anthony L. Kovac, MD

Neuromuscular Blocking Agents (NMBAs): Multidisciplinary Approach to Care – Matt L. Kirkland, MD, FACS

Faculty

Matt L. Kirkland, MD, FACS
Clinical Associate Professor of Surgery
Director Bariatric Surgery Program
Pennsylvania Hospital
Philadelphia, PA

Disclosure: No relevant financial relationships to disclose.


Anthony L. Kovac, MD
Kasumi Arakawa Professor of Anesthesiology
University of Kansas Medical Center
Kansas City, KS

Disclosure:
Contracted Research: Merck


Cheryl L. Nimmo, DNP, MSHSA, CRNA
Associate Clinical Professor
Program Director Nurse Anesthesia
University of New England
Portland, ME

Disclosure: No relevant financial relationships to disclose.

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology™ (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

This program has been prior approved by the American Association of Nurse Anesthesiology for 0.75 Class A CE credits; Code Number 1041138; Expiration Date 8/30/2022.

AANA designates this program as meeting the criteria for up to 0.50 CE Credits in pharmacology/therapeutics.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Only 1 attempt to pass the posttest will be permitted. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or AANA Class A CE Credit Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Surgery Presentations

0.75 AANA / CME / MOCA
Vindico Medical Education
Reversing Neuromuscular Blockade: Assessing Current and Emerging Therapies for Improved Outcomes

Reversing Neuromuscular Blockade: Assessing Current and Emerging Therapies for Improved Outcomes

Start

Activity Details

Free CME with MOCA/AANA
0.75 AMA PRA Category 1 Credit(s)™ with ABA MOCA 2.0; AANA Class A CE Credits
Released: August 31, 2021
Expires: August 30, 2022
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is anesthesiologists, surgeons, nurse anesthetists, and other health care professionals involved in the management of patients undergoing anesthesia.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate the benefits and limitations of current reversal agents including best practices for their use and the value of appropriate monitoring.
  • Apply the latest clinical evidence of current and emerging therapies for the reversal of neuromuscular blocking agents.
  • Utilize a multidisciplinary approach to manage surgical patients in need of deep neuromuscular blockade.
  • Utilize best practices for monitoring patients undergoing neuromuscular blockade.

Activity Description

The introduction of neuromuscular blockade agents (NMBAs) revolutionized the field of anesthesia. However, termination of the effects of these agents remains elusive, and they still have the potential for causing significant adverse outcomes. The cholinesterase inhibitor drugs first used to reverse curare have traditionally been used for reversing all NMBAs, but due to the limitations of these agents and the complications of residual neuromuscular block, development of improved reversal agents has been a priority. A new class of drugs—selective relaxant binding agents—may overcome the limitations of cholinesterase inhibitors, quickly reversing both shallow and deep levels of aminosteroid neuromuscular block. In this educational activity, utilizing an interactive infographic format, expert faculty review the benefits as well as the limitations of current and emerging reversal agents; best practices for monitoring patients undergoing neuromuscular blockade; and the importance of a multidisciplinary approach when managing patients in the surgical setting.

Agenda

Conventional Reversal Agents: Pros and Cons, Best Practices for Monitoring – Cheryl L. Nimmo, DNP, MSHSA, CRNA

Neuromuscular Blockade (NMB) Therapies: Where We Are and Where We Are Going – Anthony L. Kovac, MD

Neuromuscular Blocking Agents (NMBAs): Multidisciplinary Approach to Care – Matt L. Kirkland, MD, FACS

Faculty

Matt L. Kirkland, MD, FACS
Clinical Associate Professor of Surgery
Director Bariatric Surgery Program
Pennsylvania Hospital
Philadelphia, PA

Disclosure: No relevant financial relationships to disclose.


Anthony L. Kovac, MD
Kasumi Arakawa Professor of Anesthesiology
University of Kansas Medical Center
Kansas City, KS

Disclosure:
Contracted Research: Merck


Cheryl L. Nimmo, DNP, MSHSA, CRNA
Associate Clinical Professor
Program Director Nurse Anesthesia
University of New England
Portland, ME

Disclosure: No relevant financial relationships to disclose.

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology™ (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

This program has been prior approved by the American Association of Nurse Anesthesiology for 0.75 Class A CE credits; Code Number 1041138; Expiration Date 8/30/2022.

AANA designates this program as meeting the criteria for up to 0.50 CE Credits in pharmacology/therapeutics.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Only 1 attempt to pass the posttest will be permitted. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or AANA Class A CE Credit Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME with MOCA/AANA
0.75 AMA PRA Category 1 Credit(s)™ with ABA MOCA 2.0; AANA Class A CE Credits
Released: August 31, 2021
Expires: August 30, 2022
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is anesthesiologists, surgeons, nurse anesthetists, and other health care professionals involved in the management of patients undergoing anesthesia.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate the benefits and limitations of current reversal agents including best practices for their use and the value of appropriate monitoring.
  • Apply the latest clinical evidence of current and emerging therapies for the reversal of neuromuscular blocking agents.
  • Utilize a multidisciplinary approach to manage surgical patients in need of deep neuromuscular blockade.
  • Utilize best practices for monitoring patients undergoing neuromuscular blockade.

Activity Description

The introduction of neuromuscular blockade agents (NMBAs) revolutionized the field of anesthesia. However, termination of the effects of these agents remains elusive, and they still have the potential for causing significant adverse outcomes. The cholinesterase inhibitor drugs first used to reverse curare have traditionally been used for reversing all NMBAs, but due to the limitations of these agents and the complications of residual neuromuscular block, development of improved reversal agents has been a priority. A new class of drugs—selective relaxant binding agents—may overcome the limitations of cholinesterase inhibitors, quickly reversing both shallow and deep levels of aminosteroid neuromuscular block. In this educational activity, utilizing an interactive infographic format, expert faculty review the benefits as well as the limitations of current and emerging reversal agents; best practices for monitoring patients undergoing neuromuscular blockade; and the importance of a multidisciplinary approach when managing patients in the surgical setting.

Agenda

Conventional Reversal Agents: Pros and Cons, Best Practices for Monitoring – Cheryl L. Nimmo, DNP, MSHSA, CRNA

Neuromuscular Blockade (NMB) Therapies: Where We Are and Where We Are Going – Anthony L. Kovac, MD

Neuromuscular Blocking Agents (NMBAs): Multidisciplinary Approach to Care – Matt L. Kirkland, MD, FACS

Faculty

Matt L. Kirkland, MD, FACS
Clinical Associate Professor of Surgery
Director Bariatric Surgery Program
Pennsylvania Hospital
Philadelphia, PA

Disclosure: No relevant financial relationships to disclose.


Anthony L. Kovac, MD
Kasumi Arakawa Professor of Anesthesiology
University of Kansas Medical Center
Kansas City, KS

Disclosure:
Contracted Research: Merck


Cheryl L. Nimmo, DNP, MSHSA, CRNA
Associate Clinical Professor
Program Director Nurse Anesthesia
University of New England
Portland, ME

Disclosure: No relevant financial relationships to disclose.

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology™ (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

This program has been prior approved by the American Association of Nurse Anesthesiology for 0.75 Class A CE credits; Code Number 1041138; Expiration Date 8/30/2022.

AANA designates this program as meeting the criteria for up to 0.50 CE Credits in pharmacology/therapeutics.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Only 1 attempt to pass the posttest will be permitted. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or AANA Class A CE Credit Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 AANA / CME / MOCA
Vindico Medical Education
Neuromuscular Blockade Reversal: Navigating the Therapeutic Landscape to Achieve Optimal Patient Outcomes

Neuromuscular Blockade Reversal: Navigating the Therapeutic Landscape to Achieve Optimal Patient Outcomes

Start

Activity Details

Free CME/MOCA/AANA
1.0 AMA PRA Category 1 Credit(s)™ with ABA MOCA 2.0; AANA Class A CE Credit
Released: 6/30/2021
Expires: 6/29/2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is anesthesiologists, surgeons, nurse anesthetists, and other health care professionals involved in the management of patients undergoing anesthesia.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the benefits and limitations of current reversal agents.
  • Examine the best practices for the use of neuromuscular blocking agents, including the value of appropriate monitoring.
  • Assess the most recent evidence regarding the safety and efficacy of current and emerging therapies for the reversal of neuromuscular blocking agents.
  • Evaluate the significance of a multidisciplinary approach to manage surgical patients in need of deep neuromuscular blockade.

Activity Description

The introduction of neuromuscular blockade agents (NMBAs) revolutionized the field of anesthesia. However, termination of the effects of these agents remains elusive, and they still have the potential for significant adverse outcomes. The cholinesterase inhibitor drugs first used to reverse curare have traditionally been used for reversing all NMBAs, but due to the limitations of these agents and the complications of residual neuromuscular block, development of improved reversal agents has been underway. A new class of drugs, selective relaxant binding agents, may overcome the limitations of cholinesterase inhibitors and quickly reverse both shallow and deep levels of aminosteroid neuromuscular block. In this podcast series, expert faculty review the benefits and limitations of current and emerging reversal agents, best practices for monitoring patients undergoing neuromuscular blockade, and the importance of a multidisciplinary approach when managing patients in the surgical setting.

Agenda

Best Practices for Monitoring Neuromuscular Blockade with J. Ross Renew, MD, FASA, FASE, and Anthony L. Kovac, MD
Benefits and Drawbacks of Conventional Reversal Agents with J. Ross Renew, MD, FASA, FASE, and Richard Pence, CRNA, MHA
Current and Emerging NMB Therapies with  J. Ross Renew, MD, FASA, FASE, and Anthony L. Kovac, MD
Significance of a Multidisciplinary Approach for NMBAs with J. Ross Renew, MD, FASA, FASE, and Richard Pence, CRNA, MHA

Activity Chair

J. Ross Renew, MD, FASA, FASE
Assistant Professor of Anesthesiology
Mayo Clinic
Jacksonville, FL

Disclosure: Contracted Research (paid to institution): Merck

Faculty

Anthony L. Kovac, MD
Kasumi Arakawa Professor of Anesthesiology
University of Kansas Medical Center
Kansas City, KS

Disclosure: Speakers Bureau: Mundipharma
Contracted Research: Merck

Richard Pence, CRNA, MHA
Instructor in Anesthesiology, Mayo Clinic College of Medicine
Mayo Clinic
Jacksonville, FL

Disclosure: No relevant financial relationships to disclose.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology™ (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

This program has been prior approved by the American Association of Nurse Anesthetists for 1.00 Class A CE credits; Code Number 1040742; Expiration Date 6/29/2022.

AANA designates this program as meeting the criteria for up to 0.75 CE Credits in Pharmacology/Therapeutics.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, complete the posttest, learner assessment and program evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. Only one (1) attempt to pass the posttest will be permitted. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or an AANA Class A CE Credit Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOCA/AANA
1.0 AMA PRA Category 1 Credit(s)™ with ABA MOCA 2.0; AANA Class A CE Credit
Released: 6/30/2021
Expires: 6/29/2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is anesthesiologists, surgeons, nurse anesthetists, and other health care professionals involved in the management of patients undergoing anesthesia.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the benefits and limitations of current reversal agents.
  • Examine the best practices for the use of neuromuscular blocking agents, including the value of appropriate monitoring.
  • Assess the most recent evidence regarding the safety and efficacy of current and emerging therapies for the reversal of neuromuscular blocking agents.
  • Evaluate the significance of a multidisciplinary approach to manage surgical patients in need of deep neuromuscular blockade.

Activity Description

The introduction of neuromuscular blockade agents (NMBAs) revolutionized the field of anesthesia. However, termination of the effects of these agents remains elusive, and they still have the potential for significant adverse outcomes. The cholinesterase inhibitor drugs first used to reverse curare have traditionally been used for reversing all NMBAs, but due to the limitations of these agents and the complications of residual neuromuscular block, development of improved reversal agents has been underway. A new class of drugs, selective relaxant binding agents, may overcome the limitations of cholinesterase inhibitors and quickly reverse both shallow and deep levels of aminosteroid neuromuscular block. In this podcast series, expert faculty review the benefits and limitations of current and emerging reversal agents, best practices for monitoring patients undergoing neuromuscular blockade, and the importance of a multidisciplinary approach when managing patients in the surgical setting.

Agenda

Best Practices for Monitoring Neuromuscular Blockade with J. Ross Renew, MD, FASA, FASE, and Anthony L. Kovac, MD
Benefits and Drawbacks of Conventional Reversal Agents with J. Ross Renew, MD, FASA, FASE, and Richard Pence, CRNA, MHA
Current and Emerging NMB Therapies with  J. Ross Renew, MD, FASA, FASE, and Anthony L. Kovac, MD
Significance of a Multidisciplinary Approach for NMBAs with J. Ross Renew, MD, FASA, FASE, and Richard Pence, CRNA, MHA

Activity Chair

J. Ross Renew, MD, FASA, FASE
Assistant Professor of Anesthesiology
Mayo Clinic
Jacksonville, FL

Disclosure: Contracted Research (paid to institution): Merck

Faculty

Anthony L. Kovac, MD
Kasumi Arakawa Professor of Anesthesiology
University of Kansas Medical Center
Kansas City, KS

Disclosure: Speakers Bureau: Mundipharma
Contracted Research: Merck

Richard Pence, CRNA, MHA
Instructor in Anesthesiology, Mayo Clinic College of Medicine
Mayo Clinic
Jacksonville, FL

Disclosure: No relevant financial relationships to disclose.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology™ (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

This program has been prior approved by the American Association of Nurse Anesthetists for 1.00 Class A CE credits; Code Number 1040742; Expiration Date 6/29/2022.

AANA designates this program as meeting the criteria for up to 0.75 CE Credits in Pharmacology/Therapeutics.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, complete the posttest, learner assessment and program evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. Only one (1) attempt to pass the posttest will be permitted. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or an AANA Class A CE Credit Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com